Alto Neuroscience (ANRO) Other financing activities (2023 - 2026)

Alto Neuroscience (ANRO) posted Other financing activities of $703000.0 for Q4 2025, up 234.16% sequentially from -$524000.0 in Q3 2025.

Alto Neuroscience (ANRO) Other financing activities (2023 - 2026) Analysis & Trends

Alto Neuroscience has reported Other financing activities for 3 years, with the latest figure at $703000.0 in Q4 2025.

Quarterly Other financing activities changed N/A year-over-year to $703000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $505000.0 (up 155.05% YoY) and the FY2025 annual result came in at $703000.0, down 99.49% from the prior year.
Other financing activities improved to $703000.0 in Q4 2025 per ANRO's latest filing, from -$524000.0 in the prior quarter.
Over five years, Other financing activities peaked at $137.6 million in Q1 2024 and troughed at -$137.6 million in Q2 2024.
A 3-year average of $15.4 million and a median of $198000.0 in 2025 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 320051.16% in 2024, down 320051.16% in 2024.
Over 3 years, Other financing activities stood at -$43000.0 in 2023, then jumped by 320051.16% to $137.6 million in 2024, then slumped by 99.49% to $703000.0 in 2025.
According to Business Quant data, Other financing activities over the past three periods registered $703000.0, -$524000.0, and $326000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Alto Neuroscience	1.13 Bn	1.13 Bn	-

Download Data